Seeing Is Believing
Currently out of the existing stock ratings of Stephen Unger, 67 are a BUY (90.54%), 6 are a HOLD (8.11%), 1 are a SELL (1.35%).
Analyst Stephen Unger works with a stock forecast success ratio of 87.36% fulfilled within 133.46 days on average.
Stephen Unger’s has documented 127 price targets and ratings displayed on 13 stocks. The coverage was on Healthcare, Technology, Industrials sectors.
Most recent stock forecast was given on NEO, NeoGenomics at 29-Mar-2022.
Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for NEO (NEOGENOMICS) at 1/3/2019. The price target of $14 was fulfilled within 6 days with a profit of $1.86 (15.32%) receiving and performance score of 25.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
102
$19.8 (24.09%)
70
1 months 28 days ago
1/2 (50%)
$13.67 (15.48%)
76
Hold
81
$-1.2 (-1.46%)
78
2 months 15 days ago
6/6 (100%)
$1 (1.25%)
168
Buy
90
$7.8 (9.49%)
65
2 months 15 days ago
3/4 (75%)
$10 (12.50%)
104
Hold
62
$-20.2 (-24.57%)
79
5 months 26 days ago
4/4 (100%)
$3.26 (5.55%)
290
Sell
59
$-23.2 (-28.22%)
70
6 months 11 days ago
3/3 (100%)
$-1.09 (-1.81%)
236
What Year was the first public recommendation made by Stephen Unger?